Progressive transfusion and growth factor independence with adjuvant sertraline in low risk myelodysplastic syndrome treated with an erythropoiesis stimulating agent and granulocyte-colony stimulating factor

Refractoriness to growth factor therapy is commonly associated with inferior outcome in patients with low-risk myelodysplastic syndrome (LR-MDS) who require treatment for cytopenias. However, the mechanisms leading to refractoriness are unknown. Here we describe a clinically depressed 74-year-old ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Nautiyal, Kirtan, Li, Rui, Yellapragada, Sarvari, Thiagarajan, Perumal, Mims, Martha, Rivero, Gustavo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4327762/
https://www.ncbi.nlm.nih.gov/pubmed/25709889
http://dx.doi.org/10.1016/j.lrr.2014.11.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4327762/
https://www.ncbi.nlm.nih.gov/pubmed/25709889
http://dx.doi.org/10.1016/j.lrr.2014.11.001

Ejemplares similares